Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid production.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
## Adult Dosing
* **Healing of erosive esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks.
* **Maintenance of healing of erosive esophagitis:** 40 mg orally once daily. Some patients may be managed on 20 mg orally once daily.
* **Pathological hypersecretory conditions:** 40 mg orally or intravenously twice daily. Doses may be increased as needed. Doses up to 240 mg daily have been administered intravenously.
## Pediatric Dosing
* **GERD (oral, age 5 to 11 years):** 20 mg orally once daily for up to 4 weeks.
* **GERD (oral, age 12 to 16 years):** 40 mg orally once daily for up to 8 weeks.
* **Erosive esophagitis (oral, age 5 to 11 years):** 20 mg orally once daily for up to 8 weeks.
* **Erosive esophagitis (oral, age 12 to 16 years):** 40 mg orally once daily for up to 8 weeks.
* **Intravenous (IV) dosing in pediatric patients is not established.**
## Dose Adjustments
* **Hepatic Impairment:** Maximum dose of 20 mg orally or IV once daily.
## Contraindications
* Known hypersensitivity to pantoprazole, any component of the formulation, or any other substituted benzimidazole.
## Adverse Effects
* Common: Headache, diarrhea, nausea, abdominal pain, vomiting, dizziness, flatulence.
* Serious: *Clostridium difficile*-associated diarrhea, bone fracture (hip, wrist, spine), hypomagnesemia (can be asymptomatic and may lead to serious adverse events like QT prolongation, seizures, tetany, or arrhythmias), vitamin B12 deficiency, lupus erythematosus (cutaneous and systemic).
## Key Drug Interactions
* **Antiretrovirals:** Reduced absorption of drugs dependent on gastric pH (e.g., rilpivirine, nelfinavir). Avoid concomitant use.
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity. Consider temporary discontinuation of pantoprazole if high-dose methotrexate is used.
* **CYP2C19 Substrates:** Pantoprazole inhibits CYP2C19. May affect metabolism of drugs like clopidogrel (reduced active metabolite), citalopram, and diazepam.
* **Warfarin:** Increased INR and bruising in patients receiving warfarin and PPIs. Monitor INR closely.
## Monitoring
* Monitor for signs and symptoms of *C. difficile*-associated diarrhea.
* Monitor electrolytes (magnesium, potassium, sodium) especially with prolonged use or in patients on other medications that may cause hypomagnesemia.
* Monitor bone mineral density in patients at risk for osteoporosis.
* Monitor for signs of vitamin B12 deficiency with long-term use.
* Monitor for cutaneous or systemic lupus erythematosus.
## Clinical Pearls
* Administer 30 minutes before a meal.
* Oral formulations (tablets and delayed-release capsules) are enteric-coated and should not be crushed or chewed. They can be sprinkled on applesauce.
* IV infusion should be administered over at least 2 minutes or as an infusion over 15 minutes.
* Long-term use of PPIs has been associated with an increased risk of fractures, hypomagnesemia, and vitamin B12 deficiency. Consider the risks versus benefits for extended therapy.
***
*This information is intended for healthcare professionals. Always consult the official prescribing information and relevant clinical guidelines for the most current and complete drug information before making any clinical decisions.*
